Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Dec 1;52(12):728-733.
doi: 10.1097/OLQ.0000000000002220. Epub 2025 Jul 10.

"It's Been a Very Liberating Experience": Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Men Who Have Sex With Men

Rodney Perkins, Rob J Fredericksen  1 , Katerina A Christopoulos  2 , Kristin Beima-Sofie  3 , Stephanie E Cohen, Julia C Dombrowski, Aurnell Dright  3 , Saraniesha Gardner  4 , Pamela Kohler, Anne F Luetkemeyer  2 , Jillian Pintye  5 , Connie Celum
Affiliations
Clinical Trial

"It's Been a Very Liberating Experience": Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention and Experiences With Sexual Pleasure by Men Who Have Sex With Men

Rodney Perkins et al. Sex Transm Dis. .

Abstract

Background: Pleasure is a key component in sexual decision making. Doxycycline postexposure prophylaxis (doxy-PEP) is a novel intervention for sexually transmitted infection prevention for men who have sex with men (MSM) that may influence sexual experiences. Using the Sexual Health Model, we assessed whether doxy-PEP use influences intimacy and sexual pleasure among MSM.

Methods: From November 2021 to December 2022, we conducted individual interviews with MSM living with and without HIV enrolled in a clinical trial of doxy-PEP (NCT03980223). Participants were purposively sampled to capture a range of doxy-PEP use frequency. Interviews explored how doxy-PEP influenced sexual health and decision making, pleasure, intimacy, and relationships. Interview transcripts and debrief reports were thematically analyzed.

Results: We interviewed 43 DoxyPEP trial participants, of whom the median age was 38 years (interquartile range, 34-46 years), 63% identified as White, 18% as Black, and 38% as Hispanic. Nineteen (44%) were living with HIV. Participants reported that doxy-PEP use improved their quality of life by providing peace of mind and resulted in more enjoyable sex experiences and increased intimacy. Participants felt that doxy-PEP provided freedom to choose about condom use and selection of partners, and supported communication with sexual partners about sexually transmitted infection prevention. These positive experiences with doxy-PEP were similar in men living with and without HIV.

Conclusions: Men who have sex with men reported that doxy-PEP use improved their sexual pleasure and intimacy with partners. Recognizing these positive aspects of doxy-PEP is essential for tailoring messaging and counseling about doxy-PEP and could motivate doxy-PEP use.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest and Sources of Funding: The authors have no financial conflicts of interest to declare. This study was also funded by the US National Institutes of Health Division of Microbiology and Infectious Diseases under award number R01AI143439, Hester McLaws Nursing Fund, and the Center for Global Health Nursing Scholarship. The funders had no role in study design, data collection and analysis, publication decision, or manuscript preparation

References

    1. Control CfD. National Overview of STIs in 2023. Available at: https://www.cdc.gov/sti-statistics/annual/summary.html . Accessed June 20, 2025.
    1. Gaillard T, Madamet M, Pradines B. Tetracyclines in malaria. Malar J 2015; 14:445.
    1. Peyriere H, Makinson A, Marchandin H, et al. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother 2018; 73:553–563.
    1. Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023; 388:1296–1306.
    1. Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: An open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018; 18:308–317.

Publication types

MeSH terms